Day 4 Session:
Addiction Psychiatry Annual REVIEW: 2026 Highest Impact Publications
Carla Marienfeld, MD, DFAPA, DFASAM — Chairperson Professor of Clinical Psychiatry, UC San Diego
Joshua D. Lee, MD, MSc — Presenter NYU Grossman School of Medicine
Brian Hurley, MD, MBA, FAPA, DFASAM — Presenter LA County Department of Public Health
Daryl Shorter, MD — Discussant Baylor College of Medicine
Larissa Mooney, MD — Discussant Medical University of South Carolina
This session covers the year's highest-impact publications so you can catch up on the research in a single session.
At the conclusion of this session, participants should be able to:
1. Summarize the highest-impact, evidence-based addiction psychiatry literature from mid-2025 through mid-2026, spanning opioids/fentanyl and overdose, cannabis, nicotine, GLP-1 receptor agonists, behavioral addictions, alcohol, pregnancy, and stimulant use disorder.
2. Recognize emerging clinical threats, including medetomidine-adulterated fentanyl withdrawal, rising cannabis-associated psychosis after commercial legalization, and behavioral addictions such as gambling and addictive screen use.
3. Describe new pharmacotherapy and treatment-delivery evidence, including GLP-1 receptor agonists for alcohol use disorder, extended-release buprenorphine in pregnancy, contingency management for stimulant use disorder, and mirtazapine for methamphetamine use disorder.
4. Discuss policy, systems, and public health implications of this year's literature, including regulatory, reimbursement, and implementation barriers to evidence-based care.